There is interest in determining whether antiangiogenic therapies can act synergistically with checkpoint blockade in the setting of recurrent ovarian cancer.
The benefit was seen in an all-comers population, according to the presenters at ESMO Congress 2019.
Results of a prospective study comparing effectiveness of ultrasound screening and salpingo-oophorectomy in preventing ovarian cancer are presented.
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.
Novel noncontraceptive benefit seen for all intrauterine devices.
Researchers sought to analyze how pain management affects quality of life and overall survival for patients with recurrent ovarian cancer.
Survivors of NHL should be offered genetic counseling.
Black women with cervical cancer were less likely to receive brachytherapy and had poorer survival, suggesting brachytherapy may mediate survival outcomes.
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
